Rick E. Winningham - 02 Apr 2024 Form 4 Insider Report for Theravance Biopharma, Inc. (TBPH)

Reporting relationship: CHIEF EXECUTIVE OFFICER, Director
Issuer ticker: TBPH
Reported as of: 02 Apr 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Apr 2024, 18:17:33 UTC
Prior SEC filing: 19 Mar 2024
Next SEC filing: 17 May 2024
Source filing: View source filing
Reporting owner signature: /s/ Brett A. Grimaud, Attorney-in-Fact

Key filing fact

Rick E. Winningham filed Form 4 for Theravance Biopharma, Inc. (TBPH) on 04 Apr 2024.

Key facts

This page summarizes Rick E. Winningham's Form 4 filing for Theravance Biopharma, Inc. (TBPH).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 04 Apr 2024, 18:17.

Change

Previous filing in this sequence was filed on 19 Mar 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TBPH transaction

Ordinary Shares

Award

Transaction value: $0
Shares: +300,000
Change %: +19%
Price: $0.000000
Shares after: 1,850,573
Date: 02 Apr 2024
Ownership: Direct
Footnotes: F1

TBPH holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 3,900
Date: 02 Apr 2024
Ownership: As Custodian

TBPH holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 92,567
Date: 02 Apr 2024
Ownership: By Trust

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

On April 2, 2024, the reporting person was granted 300,000 RSUs. 150,000 RSUs are subject to service-based vesting conditions and the remaining 150,000 RSUs vest based on the achievement of share price appreciation targets as well as continued employment.